Safety of omalizumab treatment in patients with chronic spontaneous urticaria and <scp>COVID‐19</scp>
Maria Passante, Maddalena Napolitano, Stefano Dastoli, Luigi Bennardo, Gabriella Fabbrocini, Steven Paul Nisticò, Cataldo Patruno
Abstract
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Topics & Concepts
MedicineOmalizumabCoronavirus disease 2019 (COVID-19)Chronic urticaria2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DermatologyVirologyImmunologyAntibodyInternal medicineImmunoglobulin EDiseaseInfectious disease (medical specialty)OutbreakUrticaria and Related ConditionsDrug-Induced Adverse ReactionsAsthma and respiratory diseases